Home›Compare›Breeze Meds vs HumeCare+

Breeze Meds vs HumeCare+: Which Is Better?

Head-to-head comparison of Breeze Meds and HumeCare+ based on our independent scoring across trust, value, experience, product range, and reputation — plus real pricing for the treatments they both offer.

Our Verdict

HumeCare+ scores higher overall in our independent evaluation (54.2/100 vs 51.3/100), leading on trust & safety, experience, product range, reputation. Breeze Meds comes out ahead on value. Breeze Meds has the lower entry price (from $169/mo vs $199/mo), so the better value depends on which treatment you need.

51
Breeze Meds
Below Average

Breeze Meds is a new GLP-1 and NAD+ storefront based in Marietta, GA. Prescribing goes through the Lion MD network, and it shares its pharmacies and prescribers with Synergy Rx and Care Bare Rx.

Visit Breeze Meds
54
HumeCare+
Below Average

HumeCare+ is the GLP-1 weight-loss program from smart-scale maker Hume Health. It bundles clinician-prescribed GLP-1 medication with a Hume Pod body-composition scale and app tracking, starting at $199/mo.

Visit HumeCare+

Score Breakdown

DimensionBreeze MedsHumeCare+
Overall Score51.3/10054.2/100 ✓
Trust & Safety30%50/10052/100 ✓
Value25%62/100 ✓60/100
Experience20%50/10058/100 ✓
Product Range15%45/10050/100 ✓
Reputation10%40/10045/100 ✓

At a Glance

Founded——
HeadquartersMarietta, GAWilmington, DE
Publicly tradedNoNo
Treatment categories21
Treatments listed32
Starting price$169/mo$199/mo

Pricing Where They Compete

Prices shown are based on our most recent research and may not reflect current pricing. Telehealth providers update their pricing frequently. Always verify pricing directly with the provider before purchasing.

CategoryBreeze MedsHumeCare+
Weight Loss / GLP-1$199
GLP-1 Weight Loss Injections (compounded semaglutide)
$199
HumeCare+ Compounded Semaglutide Protocol

Breeze Meds

+Names its four dispensing pharmacies (Belmar, Strive, Epiq Scripts, Casa Pharma Rx) and two supervising physicians with NPI numbers
+Entry GLP-1 price of $199 is competitive for compounded semaglutide
+Claims service in all 50 states, with HSA/FSA eligibility
−The sales page does not specify the medication, dose, billing interval or compounded-vs-branded status behind the $199 price
−No Trustpilot or BBB history; online footprint is mostly paid press-release 'reviews'
−Same prescribers and pharmacies as Synergy Rx and Care Bare Rx, so it offers no independent clinical operation
Read the full Breeze Meds review →

HumeCare+

+Includes a Hume Pod body-composition scale (listed at $352) and monthly scans, so patients can track fat versus lean-mass change during GLP-1 treatment
+Protocol adds glycine, B12 and B6 aimed at muscle preservation and tolerability
+Advertises a refund if the patient does not lose 10% of body weight within 6 months (terms apply); FSA/HSA eligible
−Parent Hume Health holds a BBB F rating with 348 complaints closed in three years and a 3.5/5 Trustpilot score, mostly about refunds, device accuracy and support
−The prescribing medical group, the dispensing pharmacy and the state list are not published, and full pricing only appears after intake
−3-month minimum commitment; $199/mo headline requires a $100 welcome credit
Read the full HumeCare+ review →

Breeze Meds vs HumeCare+ — FAQ

Is Breeze Meds better than HumeCare+?

▾

HumeCare+ scores higher overall in our independent evaluation (54.2/100 vs 51.3/100), leading on trust & safety, experience, product range, reputation. Breeze Meds comes out ahead on value. Breeze Meds has the lower entry price (from $169/mo vs $199/mo), so the better value depends on which treatment you need.

Is Breeze Meds or HumeCare+ cheaper?

▾

Breeze Meds has the lower starting price (from $169/mo vs $199/mo for HumeCare+). Starting prices are for the cheapest treatment each offers — compare the specific treatment you need, and check what each price includes.

What do Breeze Meds and HumeCare+ both offer?

▾

Both platforms treat Weight Loss / GLP-1. Breeze Meds covers 2 treatment categories total and HumeCare+ covers 1.

Still deciding?